These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29536605)

  • 1. Effects of intranasal insulin on endogenous glucose production in insulin-resistant men.
    Xiao C; Dash S; Stahel P; Lewis GF
    Diabetes Obes Metab; 2018 Jul; 20(7):1751-1754. PubMed ID: 29536605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal insulin suppresses endogenous glucose production in humans compared with placebo in the presence of similar venous insulin concentrations.
    Dash S; Xiao C; Morgantini C; Koulajian K; Lewis GF
    Diabetes; 2015 Mar; 64(3):766-74. PubMed ID: 25288674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamic and Striatal Insulin Action Suppresses Endogenous Glucose Production and May Stimulate Glucose Uptake During Hyperinsulinemia in Lean but Not in Overweight Men.
    Heni M; Wagner R; Kullmann S; Gancheva S; Roden M; Peter A; Stefan N; Preissl H; Häring HU; Fritsche A
    Diabetes; 2017 Jul; 66(7):1797-1806. PubMed ID: 28174292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Intranasal Insulin on Triglyceride-Rich Lipoprotein Particle Production in Healthy Men.
    Xiao C; Dash S; Stahel P; Lewis GF
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1776-1781. PubMed ID: 28751575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the specific effects of intranasal glucagon on glucose production and lipid concentration in healthy men during a pancreatic clamp.
    Dash S; Xiao C; Stahel P; Koulajian K; Giacca A; Lewis GF
    Diabetes Obes Metab; 2018 Feb; 20(2):328-334. PubMed ID: 28730676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance in obesity can be reliably identified from fasting plasma insulin.
    ter Horst KW; Gilijamse PW; Koopman KE; de Weijer BA; Brands M; Kootte RS; Romijn JA; Ackermans MT; Nieuwdorp M; Soeters MR; Serlie MJ
    Int J Obes (Lond); 2015 Dec; 39(12):1703-9. PubMed ID: 26155920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
    Henry RR; Mudaliar S; Ciaraldi TP; Armstrong DA; Burke P; Pettus J; Garhyan P; Choi SL; Jacober SJ; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen N; Sinha VP; Linnebjerg H
    Diabetes Care; 2014 Sep; 37(9):2609-15. PubMed ID: 24947791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
    Horvath K; Bock G; Regittnig W; Bodenlenz M; Wutte A; Plank J; Magnes C; Sinner F; Fürst-Recktenwald S; Theobald K; Pieber TR
    Diabetes Obes Metab; 2008 Jun; 10(6):484-91. PubMed ID: 17764465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
    Gastaldelli A; Cusi K; Pettiti M; Hardies J; Miyazaki Y; Berria R; Buzzigoli E; Sironi AM; Cersosimo E; Ferrannini E; Defronzo RA
    Gastroenterology; 2007 Aug; 133(2):496-506. PubMed ID: 17681171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.
    Wajcberg E; Miyazaki Y; Triplitt C; Cersosimo E; DeFronzo RA
    Diabetes Care; 2004 Dec; 27(12):2868-73. PubMed ID: 15562199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal insulin administration does not affect hepatic glucose production at systemic fasting insulin levels.
    Plomgaard P; Hansen JS; Ingerslev B; Clemmesen JO; Secher NH; van Hall G; Fritsche A; Weigert C; Lehmann R; Häring HU; Heni M
    Diabetes Obes Metab; 2019 Apr; 21(4):993-1000. PubMed ID: 30552787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men.
    Sørensen LP; Søndergaard E; Nellemann B; Christiansen JS; Gormsen LC; Nielsen S
    Diabetes; 2011 Sep; 60(9):2257-64. PubMed ID: 21810597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
    Mudaliar S; Henry RR; Ciaraldi TP; Armstrong DA; Burke PM; Pettus JH; Garhyan P; Choi SL; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen NK; Sinha VP; Linnebjerg H; Jacober SJ
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():17-24. PubMed ID: 27723226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men.
    Heni M; Wagner R; Kullmann S; Veit R; Mat Husin H; Linder K; Benkendorff C; Peter A; Stefan N; Häring HU; Preissl H; Fritsche A
    Diabetes; 2014 Dec; 63(12):4083-8. PubMed ID: 25028522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for quantifying adipose tissue insulin resistance in overweight/obese humans.
    Ter Horst KW; van Galen KA; Gilijamse PW; Hartstra AV; de Groot PF; van der Valk FM; Ackermans MT; Nieuwdorp M; Romijn JA; Serlie MJ
    Int J Obes (Lond); 2017 Aug; 41(8):1288-1294. PubMed ID: 28465607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin.
    Jazet IM; Pijl H; Frölich M; Romijn JA; Meinders AE
    Metabolism; 2005 Jun; 54(6):705-12. PubMed ID: 15931603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis.
    Bock G; Chittilapilly E; Basu R; Toffolo G; Cobelli C; Chandramouli V; Landau BR; Rizza RA
    Diabetes; 2007 Jun; 56(6):1703-11. PubMed ID: 17384334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs.
    Lowe S; Sher E; Wishart G; Jackson K; Yuen E; Brittain C; Fong SC; Clarke DO; Landschulz WH
    Drug Deliv Transl Res; 2017 Feb; 7(1):11-15. PubMed ID: 27553192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects.
    de la Peña A; Yeo KP; Linnebjerg H; Catton E; Reddy S; Brown-Augsburger P; Morrow L; Ignaut DA
    J Diabetes Sci Technol; 2015 Jul; 9(4):824-30. PubMed ID: 25697717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.